miR-548c-3p targets TRIM22 to attenuate the Peg–IFN–α therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B

Chronic hepatitis B (CHB) patients treated with interferon shows encouraging results. However, its clinical efficacy is limited by significant individual differences in treatment responses. We identified an interferon-inducible effector, TRIM22, as the likely causal target of such differential respo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral research 2023-05, Vol.213, p.105584-105584, Article 105584
Hauptverfasser:	Lin, Ni, Wang, Long, Guo, Zhaopei, Guo, Shaoying, Liu, Can, Lin, Jinpiao, Wu, Songhang, Xu, Siyi, Guo, Hongyan, Fang, Fenglin, Fu, Ya, Ou, Qishui
Format:	Artikel
Sprache:	eng
Schlagworte:	3' Untranslated Regions Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Chronic hepatitis B DNA, Viral Hepatitis B e Antigens Hepatitis B Surface Antigens Hepatitis B virus Hepatitis B, Chronic - drug therapy Humans Interferon-alpha - therapeutic use MicroRNAs - genetics Minor Histocompatibility Antigens - genetics miR-548c-3p Pegylated interferon α Polyethylene Glycols - therapeutic use Recombinant Proteins - therapeutic use Repressor Proteins Treatment Outcome TRIM22 Tripartite Motif Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!